These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 18593997)

  • 1. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
    Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Fribley A; Zeng Q; Wang CY
    Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Lun M; Zhang PL; Pellitteri PK; Law A; Kennedy TL; Brown RE
    Ann Clin Lab Sci; 2005; 35(3):251-8. PubMed ID: 16081580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
    Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.
    Macha MA; Matta A; Chauhan SS; Siu KW; Ralhan R
    Carcinogenesis; 2011 Mar; 32(3):368-80. PubMed ID: 21177768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
    Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
    Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma.
    Jackson-Bernitsas DG; Ichikawa H; Takada Y; Myers JN; Lin XL; Darnay BG; Chaturvedi MM; Aggarwal BB
    Oncogene; 2007 Mar; 26(10):1385-97. PubMed ID: 16953224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
    Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling.
    Aggarwal S; Takada Y; Singh S; Myers JN; Aggarwal BB
    Int J Cancer; 2004 Sep; 111(5):679-92. PubMed ID: 15252836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
    Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
    Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
    Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
    Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
    Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.